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Abstract
Oligomerization plays a major role in regulating the activity of many proteins, and in modulating their interactions. p53 is a
homotetrameric transcription factor that has a pivotal role in tumor suppression. Its tetramerization domain is contained
within its C-terminal domain, which is a site for numerous protein-protein interactions. Those can either depend on or
regulate p53 oligomerization. Here we screened an array of peptides derived from proteins known to bind the tetrameric
p53 C-terminal domain (p53CTD) and identified ten binding peptides. We quantitatively characterized their binding to
p53CTD using fluorescence anisotropy. The peptides bound tetrameric p53CTD with micromolar affinities. Despite the high
charge of the binding peptides, electrostatics contributed only mildly to the interactions. NMR studies indicated that the
peptides bound p53CTD at defined sites. The most significant chemical shift deviations were observed for the peptides
WS100B(81–92), which bound directly to the p53 tetramerization domain, and PKCa(281–295), which stabilized p53CTD in
circular dichroism thermal denaturation studies. Using analytical ultracentrifugation, we found that several of the peptides
bound preferentially to p53 tetramers. Our results indicate that the protein-protein interactions of p53 are dependent on
the oligomerization state of p53. We conclude that peptides may be used to regulate the oligomerization of p53.
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Introduction
Many disease-related proteins exist in equilibrium between
active and inactive oligomeric states. The oligomerization
equilibrium of these proteins is frequently regulated by post
translational modifications [1], binding of ligands [2] and solution
conditions such as pH and temperature [3], and plays a vital role
in the activity of the protein. Hence, modulating the dynamic
nature of oligomerization equilibria to affect protein activity is a
promising therapeutic strategy. We previously defined ‘‘shiftides’’
as peptides that bind preferentially to a certain oligomeric state of
a protein and shift the oligomerization equilibrium towards it. We
have demonstrated this principle for protein inhibition and
developed peptides that bound preferentially to the tetrameric
state of the HIV integrase protein (IN) and shifted the
oligomerization equilibrium towards it. These peptides inhibited
the IN enzymatic activity and inhibited HIV replication in cells
[4,5,6,7,8].
In this study we employed the shiftide principle to identify
peptides which modulate the oligomerization equilibrium of the
tumor suppressor p53. p53 is at the heart of a complex protein
network that provides one of the major anti-cancer mechanisms in
the cell [9,10]. It is a transcription factor that is activated and
accumulated in the nucleus in response to oncogenic stress.
Following its induction, p53 binds specific promoters in the
genome and activates the transcription of a wide array of target
genes, aimed at eliminating the threat of malignant transformation
[9,10,11]. p53 is mutated in over 50% of all cancer cases, with the
majority of mutations occurring in its DNA-binding core domain
[12].
p53 is active as a homotetramer [13] and its tetramerization is
mediated by a structurally independent tetramerization domain
(p53Tet, residues 326–355) [14,15] (Figure 1). Tetramerization of
p53 is vital to its function and plays a central role in the regulation
of p53 activity. The binding of p53 to DNA is highly cooperative
both at the level of dimeric p53 [16] and tetrameric p53 [17], and
oligomerization-deficient mutants of p53 bind DNA with much
lower affinities than the wild type [17]. Moreover, individual p53
core domains and oligomerization-deficient mutants of p53 can
bind half-site recognition elements, but these recognition elements
are usually not as active as full-site elements in terms of binding
and transcriptional activation [18]. Crystallographic studies have
shown that isolated p53 core domains assemble into tetramers
upon binding full-site recognition elements, with extensive
monomer-monomer interactions stabilizing the complex [19]. In
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the tetramerization domain and is shielded in p53 tetramers,
preventing nuclear export of tetramers of p53 [20]. Full-length p53
has a dissociation constant of ,20 nM for the dimer-tetramer
equilibrium and ,1.0 nM for the monomer-dimer equilibrium
[21].
The p53 C-terminal domain (p53CTD, residues 293–393) is a
hub for protein-protein interactions. Many p53CTD-interacting
proteins bind specifically to certain oligomeric forms of p53 and
thus modulate the p53 oligomerization equilibrium. Within the
S100 family, S100B, S100A2, and S100A6 specifically bind
tetrameric p53, while S100A1 binds only a monomeric mutant of
p53 [22,23,24,25]. Numerous kinases bind monomeric peptides
containing parts of the sequence of p53Tet, which are only
exposed in p53 dimers or monomers [26,27,28]. Binding of
proteins from the 14-3-3 family to the p53 negative regulatory
domain (p53-NRD, residues 361–393) was shown to activate the
DNA-binding of p53 by increasing the tetrameric fraction of p53.
The effect was shown to be dependent on the p53 phosphorylation
state [29]. Other proteins reported to bind to p53CTD are E3
ligases [30,31], tumor suppressors [32] and viral proteins [33,34].
The p53 tetramer has been shown to be stabilized by small
molecules. Short poly-arginine peptides bound p53Tet and slightly
stabilized the tetramer [35]. The structure of oligomerization
deficient mutants of p53Tet could be recovered using rationally
designed ligands [36]. Modulation of the oligomerization equilib-
rium of p53 is also possible by binding to its N-terminal
transactivation domain as in the case of p300, which binds the
four transactivation domains of p53 simultaneously and stabilizes
the tetramer [37].
In this study, ten peptides that bind p53CTD were identified by
screening a peptide array containing partially overlapping peptides
derived from proteins that bind p53CTD (Table S1) for binding
tetrameric recombinant p53CTD. We quantified and character-
ized the binding of the peptides to p53CTD using fluorescence
anisotropy and NMR, tested their effect on the thermodynamic
stability of the p53CTD using circular dichroism thermal
denaturation measurements, and studied their effect on p53
oligomerization using analytical ultracentrifugation. NMR studies
showed that the peptides bound p53CTD at defined sites. Several
of these peptides bound specifically to p53 tetramers, and one
peptide, PKCa(281–295), caused a mild increase in the thermo-
dynamic stability of the p53CTD tetramer. Our results indicate
that the protein-protein interactions of p53 are dependent on the
oligomerization state of p53. We conclude that peptides may be
used to regulate the oligomerization of p53.
Results
Screening of the Peptide Array for Binding p53CTD
We designed an array containing partially overlapping peptides
derived from proteins known to bind the p53CTD (for a list of the
proteins, see Table S1). We screened the array for binding
recombinant p53CTD, which was fully tetrameric at the
concentrations used. Screening of the array revealed ten peptides
that interacted with p53CTD (Figure 2, Table 1). The p53CTD-
interacting peptides were derived from the proteins S100B and
S100A4, Protein Kinase C a isoform (PKCa), the E3 ubiquitin
ligases Cullin 7 (Cul7) and PARC (Parkin Like Cytoplasmic
Protein), and the hsp70 family member Mortalin-2 (Mot2). To
identify the precise binding site of these peptides within the
p53CTD, we screened the array for binding chemically synthe-
sized His-tagged p53Tet (residues 326–355) and His-tagged
p53NRD (residues 361–393), using concentrations of 20 mM, at
which p53Tet is tetrameric. Of the ten peptides, nine bound to
p53NRD, while the peptide WS100B(81–92) bound to p53Tet
(Figure 2, Table 1). The peptide PKCa(281–295) bound to full
length p53CTD much more tightly than to p53NRD.
The screening revealed previously unknown binding sites for
p53CTD in several proteins. We discovered a single binding site
for p53CTD in Mot2, which is located between residues 266–280.
It was previously reported that Mot2 binds a region within p53Tet
[38], and our peptide array screening revealed that Mot2 also
binds at the negative regulatory domain of p53. In PKCa,w e
identified two binding sites for p53CTD–residues 271–295 and
residues 641–655.
The Peptides Bind Tetrameric p53CTD with Micromolar
Affinities
We synthesized the binding peptides, labeled them with
fluorescein at their N-termini and used fluorescence anisotropy
to validate the array screening results and quantify the binding of
the peptides to p53CTD. At the concentrations used, p53CTD
was tetrameric [21,24]. The peptides bound p53CTD with various
affinities. The tightest binding peptides Cul7(386–400),
WS100B(61–75) and PKCa(281–295) bound p53CTD with
dissociation constants of 5–20 mM. The very weak binders
Cul7(376–390) and PARC(386–400) showed detectable but non-
quantifiable binding (Figure 3, Table 2). The rest of the peptides
bound p53CTD with dissociation constants of 20–100 mM.
WS100A(21–35), which did not interact with p53CTD in the
array, also showed no change in anisotropy. The binding of all
peptides fit well to a 1:1 binding model, indicating that the
Figure 1. Domain structure of p53. The C-terminal domain contains
the folded tetramerization domain (red) flanked by two unfolded
domains (cyan). TAD – transactivation domain; CTD–C-terminal domain.
doi:10.1371/journal.pone.0038060.g001
Figure 2. Screening of the peptide array for binding to p53CTD
and the constructs p53Tet and p53NRD. Peptides that interacted
with p53NRD (p53 361–393) are marked in green. The peptide
WS100B(81–92) that interacted with p53Tet is marked in yellow. The
peptide PKCa(281–295) that bound more tightly to full-length p53CTD
than to p53NRD is marked in red.
doi:10.1371/journal.pone.0038060.g002
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state of p53CTD, with no change in the oligomerization state
upon binding.
The Binding of the Peptides to p53CTD is Specific and
Only Partly Electrostatic
We selected the three tightest binding peptides, Cul7(386–400),
WS100B(61–75) and PKCa(281–295), and analyzed the effect of
ionic strength on their binding to p53CTD according to equation
1 [39]:
LlnK
LlnaNaCl

~D~ v vNaCl ð1Þ
with K being the equilibrium constant, aNaCl the activity of NaCl,
and D~ v vNaCl the amount of Na
+ and Cl
2 ion pairs released to the
solution upon binding of the peptide to the protein. The number
of released ions is indicative of the contribution of electrostatic
forces to the interaction.
Fluorescence anisotropy experiments were conducted on each
of the three tightest binders in the presence of increasing NaCl
concentrations, and analyzed according to equation 1. The
binding affinity decreased with increasing ionic strength, as shown
in figure S1 for Cul7(386–400). The obtained dissociation
constants were plotted against NaCl solution activity [40]
(Figure 4). All the peptides tested exhibited a linear dependence,
indicating a contribution of ion release to the binding energy. The
slope of the curves was moderate and indicated the release of
roughly one ion-pair upon binding. A control peptide, Glu15,
consisting of a poly-glutamate chain with 15 residues released
about four times more ion pairs than the other peptides tested
(Table 3). This number correlates well with the total positive
charge of p53CTD (+5). This may indicate that while the negative
charge is important in directing the ligand towards the binding
site, the actual binding of the three strongest binding peptides is
only mildly assisted by electrostatics, and the main contributions to
binding come from more specific, close-range interactions.
Extrapolation of the data to physiological ionic strengths gave
dissociation constants of 15–50 mM for all three peptides (Table 3).
We performed
15N–
1H HSQC-NMR experiments to charac-
terize the binding of the peptides to
15N-labeled p53CTD.
Chemical shift deviations upon binding to p53CTD were
determined for four representative binding peptides and for the
non-binding peptide WS100A4(21–35) as a control. The devia-
tions are plotted against arbitrarily assigned peak numbers in
figure 5. The overlay of the
1H–
15N amide region and the side
chain peaks is given in Figure S2. All four peptides showed small
chemical shift deviations in a subset of residues. More significant
deviations were observed for the peptides PKCa(281–295) and
WS100B(81–92), especially in the side chain peaks. Side chain
nitrogen chemical shifts are very sensitive to changes in buffer
conditions, but comparison to the control peptide WS100A4(21–
35), which had a small effect on the side chain peaks, indicates that
the observed deviations are due to peptide binding. All binding
peptides induced chemical shift deviations at peaks 50–58 and 66–
68, in addition to some specific deviations, indicating a partial
overlap between the binding sites of the different peptides.
PKCa(281–295) Mildly Stabilizes p53CTD
To test the effects of the binding peptides on the stability of the
p53CTD tetramer, we used circular dichroism and followed the
effect of the peptides on the structural changes upon thermal
denaturation of p53CTD. It was previously shown that upon
heating the p53 tetramerization domain, it undergoes dissociation
of the tetramer coupled to denaturation of the monomers [41].
However, since p53CTD is already fully tetrameric at concentra-
tions above 1 mM, we used the mutant protein p53CTD L344A,
which has a dimer-tetramer dissociation constant of ,20 mM (data
not shown). The peptide PKCa(281–295) showed a small but
significant increase in the melting temperature of
DTm=2.261.0uC (Figure 6, Table 4).
The Peptides Bind Specifically to p53 Tetramers
We tested whether the peptides that bind tetrameric p53CTD
can bind specifically to tetrameric p53 in a mixture of the different
oligomers. Testing the specificity of the peptides for tetrameric p53
must be performed at very low p53 concentrations (,100 nM),
where a significant population of dimers is present in addition to
the tetramers [21]. Therefore, we used fluorescence-monitored
analytical ultracentrifugation sedimentation velocity experiments
using FlAsH-labeled full-length p53. The fluorescent label on p53
enables working at nanomolar protein concentrations and allows
for specific detection of the protein without interference from any
other molecule in the solution. This method has been extensively
used to characterize the oligomerization equilibrium of p53 and
related proteins alone and with binding proteins [21,24,29].
Table 1. Binding peptides identified in the peptide array
screening.
Name Binds to:
p53(293–393) p53(361–393) p53(326–355)
Cul7(376–390) ++2
Cul7(386–400) ++2
PKCa(271–285) ++2
PKCa(281–295) ++ (weak) 2
PKCa(641–655) ++2
Mot2(266–280) ++2
S100B(61–75) ++2
S100B(81–92) + 2 +
S100A4(61–75) ++2
PARC(386–400) ++2
doi:10.1371/journal.pone.0038060.t001
Figure 3. Binding of peptides from the array to p53CTD.
p53CTD was titrated into a solution of fluorescein-labeled peptide and
the changes in anisotropy were measured. All data were fit to a 1:1
binding model, indicated by solid lines.
doi:10.1371/journal.pone.0038060.g003
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peptides and measured the sedimentation profiles of the protein
(Figure 7). To identify the oligomeric state which preferentially
interacts with the peptides, we used the fact that p53 tetramers
exchange very slowly [42], with a t1/2 of several hours at 20uC,
and even slower at 10uC used in our experiments. Effectively,
there was little re-equilibration during the experiment, and only
oligomeric states interacting with the peptides were affected.
Sedimentation coefficients of,2 S correspond to dimers and,3S
correspond to tetramers. Presumably, sedimentation coefficients of
up to,4 S correspond to p53 tetramers bound to one or more
peptide molecules. While binding of a small peptide is unlikely to
induce significant change in the molecular weight, it may induce a
change in the shape of a molecule, leading to a more compact state
with a higher sedimentation coefficient. Most likely higher
sedimentation coefficients (.4 S) correspond to higher-order
oligomers of p53. Table 2 summarizes the results of the AUC tests.
The effect of the peptides is clearly related to their charge and
affinity to the protein. Highly charged and tight binding peptides
bound p53 tetramers at lower peptide concentrations and also
caused aggregation at excess concentrations. Peptides with a low
charge and low affinity had a small or no effect. Eight peptides
caused the tetramer peak to shift or gradually disappear while
higher p53 oligomers formed (Figure 7B). The dimer peak was
unaffected. This indicates that the peptides bound mainly to the
tetrameric fraction of the protein and some of them might have
also induced the formation of small aggregates, or bridged two or
more p53 tetramers. The behavior of the peptides was concen-
tration-dependent (Figure 7C): At low peptide concentrations (20–
50 mM) the tetramer peak started to shift, indicating binding of
peptides to the protein. At higher peptide concentrations, the
protein became saturated with bound peptides and high-order
oligomers formed, the extent of aggregation increasing with
peptide concentration. The only peptide that showed no effect was
PKCa(271–285) (Figure 7A), presumably because its binding to
p53CTD was weak (Kd=105 mM) and we could not reach a
concentration above 310 mM with it. For peptides that bound
p53CTD weakly, such as PARC(386–400) and Cul7(376–390), a
specific shift of the tetramer peak was observed but at much higher
concentrations, and no high-order oligomers were formed
(Figure 7D).
Discussion
In this study we designed a peptide array derived from proteins
known to interact with the C-terminal domain of p53 and
screened them for binding recombinant p53CTD. We character-
ized the binding of the peptides to p53CTD and the dependence
of the binding on the oligomerization state of full-length p53 by
quantitative biophysical techniques, using purified proteins and
peptides. The peptides we identified bound tetrameric p53CTD at
distinct sites with affinities as low as 5 mM, and bound specifically
to tetrameric full-length p53 in fluorescence-monitored analytical
ultracentrifugation. The peptides bound p53CTD at defined sites
as shown by NMR, and the peptide PKCa(281–295) increased the
Table 2. Binding affinities of peptides from the array to p53CTD and their effect in AUC
A.
Peptide Sequence Kd (mM
B) Charge
C AUC effect
Cul7(386–400) LDDYEEISAGDEGEF 5.360.1
D 27 Tetramer shift + high order oligomer
WS100B(61–75) WLDNDGDGECDFQEFM 7.560.2 26 Tetramer shift + high order oligomer
PKCa(281–295) EEGEYYNVPIPEGDE 1761 26 Tetramer shift + high order oligomer
Wmot2(266–280) WSTNGDTFLGGEDFDQ 4161 24 Tetramer shift + high order oligomer
WS100B(81–92) WVTTACHEFFEHE 6162 23 Tetramer shift + high order oligomer
WPKCa(641–655) WDQLVIANIDQSDFEG 6563 24 N/D: No sedimentation observed
PKCa(271–285) ASGWYKLLNQEEGEY 10569 22 No effect
S100A4(61–75) NLDSNRDNEVDFQEY 9867 24 Tetramer shift + high order oligomer
PARC(386–400) GMRVRMLDDYEEISA .400
E 22 Tetramer shift
Cul7(376–390) TLQPGMRVRMLDDYE .800
E 21 Tetramer shift
A: All peptides were amidated at their C-terminus.
B: The dissociation constant is given in mM tetramer.
C: The charge is estimated for pH=7.0.
D: The error indicated is the standard error obtained from the fit for a representative titration.
E: For Cul7(376–390) and PARC(386–400), a rough estimate of the dissociation constants was obtained by fixing the anisotropy amplitude at 0.13, since the amplitude
was 0.125–0.140 for all peptides.
doi:10.1371/journal.pone.0038060.t002
Figure 4. Ionic strength-dependent binding of the peptides to
p53CTD. ln(Kd) is plotted vs. ln(NaCl activity) for the tightest binding
peptides. The data were fit to a linear model.
doi:10.1371/journal.pone.0038060.g004
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Peptide Charge at pH =7 D~ vNaCl Estimated physiological Kd/mM
Cul7(386–400) 27 1.5160.07
A 48614
PKCa(281–295) 26 0.9860.12 48629
WS100B(61–75) 26 0.9860.09 1967
Glu15 215 4.1760.25 17613
A: The error indicated is the standard error obtained from the fit.
doi:10.1371/journal.pone.0038060.t003
Figure 5. Changes in chemical shifts of
15N-labeled p53CTD upon incubation with various peptides.
15N–
1H HSQC NMR spectra of the
protein were measured with and without peptide, and the changes in chemical shifts were calculated as (dD
1H
2+(dD
15N/5)
2)
0.
5. The left panel shows
the chemical shift deviations for backbone amide nitrogen atoms, and the right panel shows the chemical shift deviations for side chain nitrogen
atoms. Numbers on the x-axis are arbitrary serial numbers for peaks and are unrelated to residue sequence.
doi:10.1371/journal.pone.0038060.g005
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circular dichroism.
Implications on the Protein-Protein Interactions of
Tetrameric p53
The p53CTD-binding peptides identified in the array screening
were all derived from proteins known to bind the p53CTD. The
binding sites we identified for Cul7 and PARC are in agreement
with existing data [30]. We also discovered the precise binding
sites of p53CTD within PKCa and Mot2, which have not been
reported previously.
Our results demonstrate two separate p53CTD-binding sites in
the protein kinase PKCa. The major binding site is located
between residues 271–295 in the C2 domain of the protein. This is
a calcium-dependent membrane-binding domain involved in the
regulation of PKCa activity and is a hub for many protein-protein
interactions of PKCa [43]. This site is well conserved among other
members of the cPKC family (PKCbI, PKCbII and PKCc) but
not in other PKC proteins. It is located on a completely exposed,
partially structured loop in the C2 domain [44] (Figure 8A). A
weaker binding site is located between residues 641–655, on an
exposed helix in the catalytic domain of PKCa [28,43] (Figure 8B).
This site is highly conserved among all PKC proteins. It is
therefore possible that although all PKC proteins may bind
p53CTD, only members of the cPKC family can bind p53CTD
specifically and with high affinity.
Examination of the binding sites of Cul7, PARC and S100B to
p53CTD provides insights about the various contributions to the
interactions, as well as the possible dependence on the oligomeric
state of p53. The E3 ubiquitin ligases Cullin7 and PARC are
known to interact with p53 via the conserved CPH domain in their
N terminal regions [31], and have been shown to restrict p53 to
the cytoplasm and antagonize its function [30,45]. Our results
locate the interaction between p53CTD and a conserved region
spanning residues 376–400 in Cul7 and a 100% homologous
region in PARC, in excellent agreement with previously published
data [30]. This region contains two motifs that are both highly
charged and contain exposed hydrophobic and aromatic residues
(Figure 9). As seen in the NMR structure of the CPH domain of
Cul7 [31], the two motifs are fully exposed, face opposite
directions and are perpendicular. We hypothesize that the two
motifs may bind synergistically to different sites in p53CTD, or to
different monomeric subunits in tetrameric p53CTD, resulting in
a much higher affinity than each motif alone.
S100 proteins were shown to bind both the tetramerization
domain and the negative regulatory domain of p53 with affinities
in the micromolar range [22,23]. All S100 proteins bind preferably
to lower oligomeric forms of p53Tet. However, in our experiments
p53CTD was predominately tetrameric, therefore preventing the
detection of p53Tet-binding peptides derived from S100A4, and
explaining the weak binding of the p53Tet-binding peptide
derived from S100B (residues 81–92). Binding to the NRD is a
less common feature of S100 proteins. S100B binds the NRD with
a Kd of about 100 mM [23], while the binding of S100A4 to the
NRD is much weaker, in agreement with our results. S100
proteins also bind the N-terminal transactivation domain of p53,
and their affinity to p53CTD and the p53 N-terminal domain is
strongly affected by post-translational modifications [24]. We
speculate that the mechanism of binding between the proteins, and
therefore the binding sites, may vary depending on the oligomer-
ization state of p53 and other factors such as post-translational
modifications [24].
The NMR results indicated that all four representative peptides
bound p53CTD at defined sites that partially overlap, whereas the
control peptide WS100A4(21–35) showed smaller, less localized
chemical shift deviations. The peptides PKCa(281–295) and
WS100B(81–92) showed more significant chemical shift deviations
than the other peptides. This is consistent with our other results
since PKCa(281–295) increased the thermodynamic stability of
p53CTD, and WS100B(81–92) bound directly to the p53
tetramerization domain in the peptide array.
Figure 6. Thermal denaturation curves of p53CTD L344A in the
presence of peptides from the array. 20 mM protein was heated
from 25uCt o6 5 uC with or without 100 mM peptide. The data were fit to
a sigmoidal curve describing a transition between two states. Raw data
for two repeats (squares and hollow circles) are shown in the
background. The dashed lines represent the averaged melting
temperatures for both repeats.
doi:10.1371/journal.pone.0038060.g006
Table 4. Melting temperatures of p53CTD L344A in the
presence of peptides from the array.
Peptide Tm (6C)
No peptide 49.160.4
A
Cul7(386–400) 49.160.5
PKCa(281–295) 51.361.0
WS100B(81–92) 47.960.5
WS100A4(21–35) 48.260.1
A: The errors indicated are the deviation from the average of 2 repeats, except
for WS100A4, where the error indicated is the standard error obtained from the
sigmoidal fit.
doi:10.1371/journal.pone.0038060.t004
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Implications
The binding tests indicated that the peptides bound p53CTD in
its tetrameric form. Notably, in the peptide array screening, the
peptide PKCa(281–295) bound more tightly to the tetrameric full
length p53CTD than to the disordered, monomeric negative
regulatory domain (p53NRD). The AUC results confirmed these
observations: for most of the peptides, the tetramer peak was
shifted and even replaced by peaks of higher oligomers at excess
peptide concentration, while the dimer peak remained unchanged,
indicating that the peptides bind preferentially to the tetrameric
fraction of the protein. The peptides that showed a weak or no
effect were all weak binders that probably did not bind p53 tightly
enough to exert an effect. The formation of high-order oligomers
at high peptide concentrations was probably the result of non-
specific aggregation mediated by the highly charged peptide
molecules. Most peptides showed preferential binding to the p53
tetramer even though nine of the peptides bound the disordered
p53NRD. This may indicate that the peptides can bridge several
NRDs in the same tetramer, thus stabilizing the tetrameric state
and by doing so causing tighter binding to tetrameric p53.
Many proteins reported to bind p53CTD gave no interaction in
the array. Most of these proteins were previously shown to bind
directly to the p53 tetramerization domain. These proteins include
the HIV Tat protein, the protein BAF60a [46] which is part of the
chromatin remodeling complex, the protein kinases cdc2 [28] and
CK2b [27], and the transcription factor C/EBPb [47]. The
proteins S100B, S100A4, Mot2 and PKCa interacted very weakly
or not at all with p53Tet in our experiments, despite previous
reports of such interactions [23,26,38]. In general, we hardly
observed any interactions between peptides in the array and
p53Tet. This is probably because: (1) p53CTD was tetrameric at
Figure 7. Sedimentation profiles of FlAsH-labeled p53 (25–50 nM) measured in the presence of the peptides. A) PKCa(271–285) had no
significant effect on the profile. B) Peptides that shifted the tetramer peak. C) Concentration dependent behavior of the peptides. Sedimentation
profiles were measured with different concentrations of WS100B(61–75). Similar behavior was observed for the other peptides in B (data not shown).
D) Behavior of Cul7(376–390). This peptide binds p53 only weakly, and causes a shift of the tetramer peak at very high peptide concentrations. Similar
behavior was observed for PARC(386–400).
doi:10.1371/journal.pone.0038060.g007
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dimer interface of p53Tet [14,15] may interact with other
proteins, as with the Exportin receptor [20]. However, this
interface is only exposed in p53 dimers and monomers, and
therefore proteins that bind it would not be detected in our
screening; (2) The p53CTD construct we used contained no post-
translational modifications, which are known to significantly affect
the protein-protein interactions of p53 as well as its protein-DNA
interactions [24,29,48,49]. Therefore, in this study we identified a
selection of peptides which preferentially bind the tetrameric state
of p53 and do not require post-translational modifications for their
activity.
The peptides prove the concept that preferential binding to p53
tetramers can be achieved. However, the effect of the peptides on
p53 oligomerization and stability was small, as shown by the
circular dichroism measurements. The AUC results indicate that
many p53CTD-binding proteins bind specifically to tetrameric
p53. Although the peptides bound preferably to p53 tetramers, the
affinities of the peptides to p53 (.15 mM at physiological ionic
strength) were relatively weak compared to the p53 dimer-
tetramer dissociation constant and the affinity of p53 to DNA
(which are both around 20 nM). However, the binding of the full-
length proteins to p53 may be tight enough to significantly stabilize
the active tetramer.
Figure 8. Binding sites for p53CTD on two PKCa domains. A) The C2 domain of PKCa (pdb 1dsy). Residues 271–292 are colored in red. B) The
catalytic domain of PKCa (pdb 3iw4). Residues 641–655 are colored in red.
doi:10.1371/journal.pone.0038060.g008
Figure 9. NMR structure (pdb 2jng) of the Cul7 CPH domain, residues 360–440. The binding site for p53CTD is color marked as indicated in
the figure. The two views are rotated,180u with respect to each other. A) Direct view of the LDDYEE motif; B) Direct view of the DEGEF motif.
doi:10.1371/journal.pone.0038060.g009
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activity of p53. Data from multiple sources [20,23,26,27,28,38,46]
indicate that p53 may exist as dimer or monomer for significant
times in the cell – otherwise the tetramerization domain would not
be involved in so many interactions, and p53 would never be
exported from the nucleus. Therefore, the transition from a
predominately monomer/dimer population to an active tetrameric
population is a critical stage in p53 activation. Our results indicate
that the protein-protein interactions of p53 may be strongly
involved in this transition: The transition may be stimulated by
specific binding of proteins to tetrameric p53, or alternatively, the
transition to a mostly tetrameric p53 population may induce the
dissociation of previous interaction partners and the formation of
new interactions, which may be important for the proper function
of p53.
The specific binding of the peptides to tetrameric p53 may have
future therapeutic potential. One of the peptides, PKCa(281–295),
showed a slight stabilization of tetrameric p53 in circular
dichroism measurements, and bound tighter to full-length
tetrameric p53CTD than to the monomeric p53NRD in the
peptide array screening. Although currently the effect of the
peptides on p53 tetramer stability is, due to their low affinity,
currently small, less charged compounds with higher affinities
derived from these peptides may have a stronger effect on p53
oligomerization and activity.
Materials and Methods
Expression and Purification of p53CTD
The plasmid pRHislipoTEVp53CTD was constructed and the
protein was expressed and purified as described [23]. For the
expression of
15N-labeled p53CTD, C41 E.Coli cells were grown in
MOPS minimal media [50] with
15N-enriched ammonium
chloride, and grown at 37uC until the OD600 reached ,0.8.
The culture was then transferred to 17uC and 0.1 mM of isopropyl
b-D-thiogalactoside was added to induce the expression of the
protein. The cells were harvested after overnight incubation. The
protein was purified using the same protocol as the non-labeled
protein [23]. The L344A mutation was introduced into the
plasmid using the QuikChange site directed mutagenesis kit
(Strategene), and the mutant protein was expressed and purified
using the same protocol as the wild type.
Peptide Synthesis and Purification
Peptides were synthesized on a Liberty peptide synthesizer with
a Discover single mode microwave module, using standard Fmoc
chemistry. Protected amino acids were purchased from Luxem-
bourg Bio Technologies (Tel Aviv, Israel), Iris Biotech GmbH
(Marktredwitz, Germany), and Chem-Impex (Wood Dale, IL,
USA). For fluorescein labeling, the peptidyl resin was reacted with
5(6)-carboxyfluorescein (Molecular Probes
TM) as described [51].
Peptides were cleaved from the resin following a standard
procedure [33]. The peptides were purified on a Vydac C8
semipreparative column using gradients of 5% to 60% acetonitrile
in water, with 0.1% trifluoroacetic acid (TFA) in both solvents.
The mass of the peptides was measured using an Applied
Biosystems Voyager-DE Pro MALDI TOF mass spectrometer
and verified to be within 61 Da of the theoretical mass. The
purity of all peptides was verified to be .95% for non-labeled
peptides and .90% for fluorescein-labeled peptides by analytical
HPLC. The purified peptides were lyophilized from 30% acetic
acid to remove residual TFA. The concentrations of the peptides
were measured by UV absorbance at 280 nm using extinction
coefficients of 1490 M
21cm
21 for tyrosine and 5500 M
21cm
21
for tryptophan. For peptides with no tyrosine or tryptophan in the
sequence, a single tryptophan residue was added at the N-
terminus. For fluorescein-labeled peptides, absorbance was mea-
sured at 495 nm with an extinction coefficient of
65000 M
21cm
21.
Peptide Array Screening
Celluspots
TM peptide arrays were purchased from Intavis (Ko ¨ln,
Germany). The array was blocked for one hour at room
temperature with 2% skimmed milk in TBS-T (50 mM Tris
pH=7.5, 110 mM NaCl, 0.05% Tween 20), and washed three
times with TBS-T. p53CTD was diluted in 1% milk in TBS-T to
20 mM. The protein was incubated with the array overnight at
4uC. The array was washed three times with TBS-T. Protein was
detected using the FL-393 anti-p53 antibody (Santa Cruz). For
identifying the binding site of each peptide within p53CTD, the
blocking step was performed as described above, and His6–
p53(326–355) (His6-p53Tet) or His6-W-p53(361–393) (His6–
p53NRD) were diluted to 20 mM in 1% milk in TBS-T, and
incubated with the array overnight at 4uC. The array was then
washed three times with TBS-T and proteins detected using the
His-probe HRP-conjugated monoclonal antibody (Santa Cruz).
Fluorescence Anisotropy Binding Studies
Binding tests were performed in 20 mM sodium phosphate
buffer, pH=7.2, 13.5 mM NaCl. Measurements were performed
at 10uC using a PerkinElmer LS-55 luminescence spectrofluorim-
eter equipped with a Hamilton microlab 500 dispenser [52]. The
fluorescein-labeled peptides were dissolved in buffer and diluted to
a final concentration of 100 nM. 800 ml of the labeled peptide
solution were placed in a cuvette, and the protein (200 ml,1m M
monomer, dialyzed into the buffer) was titrated into the labeled
peptide in aliquots of 4–10 ml with 30 seconds mixing and 1
minute intervals. The total fluorescence and anisotropy were
measured after each addition using an excitation wavelength of
480 nm and an emission wavelength of 530 nm. The data were fit
to the following single-site model equation (equation 2):
r~r0zDr: P ½ 
P ½  zKd
ð2Þ
where r is the measured fluorescence anisotropy value, Dr is the
amplitude of the fluorescence anisotropy change from the initial
value (peptide only) to the final value (peptide in complex), r0 is the
starting anisotropy value corresponding to the free peptide, P ½  is
the protein concentration, and Kd is the dissociation constant. For
peptides that contain a cysteine in the sequence, 5 mM b-
mercaptoethanol was added to the buffer to ensure the peptide is
in its monomeric form during the titration.
Ionic strength dependence studies were conducted as above
with the following minor changes: 200 ml of protein stock were
titrated to 800 ml of 200 nM peptide. The buffer was 10 mM
sodium phosphate, pH=7.2 (ionic strength=18 mM). The ionic
strength of the buffer was modified by adding varying amounts of
2M NaCl in 10 mM sodium phosphate, pH=7.2. The temper-
ature was 25uC. Dissociation constants obtained were plotted
against saline solution activity, taken from previously published
data [53], and fit linearly.
NMR Studies
NMR studies were conducted in 20 mM NaPi, pH=7.2,
13.5 mM NaCl, 2 mM beta-mercaptoethanol, and 10% D2O.
15N–p53CTD and the peptides were dialyzed using GeBAflex
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against the experimental buffer. Samples contained 200 mM
15N–
p53CTD and 400 mM peptide. For the less soluble WS100B(81–
92), the sample contained 108 mM
15N–p53CTD and 216 mM
peptide. NMR spectra were recorded using a Bruker Avance
600 MHz DMX spectrometer operating at the proton frequency
of 600.13 MHz using a 5 mm selective probe equipped with a self-
shielded xyz-gradient coil. Experiments were conducted at 278 K
using standard Bruker pulse sequences. Spectra were processed
and analyzed with the TopSpin software package (Bruker
Analytische GmbH) and SPARKY (T.D. Goddard and D.G.
Kneller, SPARKY 3, University of California, San Francisco).
Changes in chemical shift were calculated as (dD
1H
2+(dD
15N/
5)
2)
0.5 where D
1H and D
15N represent the peak offsets in ppm in
the presence of the peptides, for the hydrogen and nitrogen
dimensions, respectively [54].
Circular Dichroism Thermal Denaturation Measurements
CD spectra were recorded on a JASCO J-810 Spectrophotom-
eter (JASCO, Japan) equipped with a Peltier thermostat using the
supplied SpectraManager software. The samples contained 20 mM
p53CTD L344A in 25 mM phosphate buffer, pH=7.2 with or
without the addition of 100 mM peptide. The sample was heated
at a rate of 50uC per hour, from 25uCt o6 5 uC and the CD reading
was taken at l=222 nm every 0.1uC with a response time of 8 s
per point. Full CD spectra of the sample (190–260 nm) were
measured at 25uC before and after the experiment to confirm the
reversibility of the denaturation process. Background scans were
conducted on the peptides in buffer alone, and subtracted from the
protein + peptide scans. The fraction of unfolded tetramer Fu was
calculated from the ellipticity by the relationship:
xunfolded~
h{hN ðÞ
hU{hN ðÞ
ð3Þ
where h is the value of ellipticity at any temperature, and hN and
hU represent the ellipticity values at the temperature where the
fully folded and fully unfolded states exist, respectively. The data
were then fit using a sigmoidal model, and Tm was defined as the
temperature at half height.
xunfolded~1{
1
1zexp T{Tm ðÞ =t ðÞ
ð4Þ
where t is a constant describing the slope of the melting curve.
Fluorescence Monitored Analytical Ultracentrifugation
The studies were performed with a quadruple mutant of p53,
(M133L/V203A/N239Y/N268D) [55], which is significantly
more stable than wild-type p53 but has similar activity and
DNA-binding properties. C-terminally FlAsH-tagged (CCPGCC)
p53 was expressed and reacted with FlAsH-EDT2 as described
[24]. This introduces a specific fluorescent label at the carboxy
terminus of p53. The protein was dialyzed against 25 mM NaPi
pH=7.2, 150 mM NaCl, 14.2 mM b-mercaptoethanol, 0.2 mg/
ml BSA and 10% glycerol. The experiments were run with a
protein concentration of 25–50 nM and with peptide concentra-
tions of up to 500 mM or to the solubility limit of the peptide. The
measurements were performed in a Beckman-Coulter Optima
XL-I ultracentrifuge with an Aviv fluorescence detection system
[29] in SedVel60K-FDS fluorescence velocity cells. The samples
were equilibrated in the cells at 10uC for 3 hours before
centrifugation. The AUC run was performed as described
[23,48] and analyzed using SedFit software [56].
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